Your session is about to expire
Anoro Ellipta vs Trelegy Ellipta
Introduction
For patients with chronic obstructive pulmonary disease (COPD) or other types of respiratory disorders, specific medications that manage and relieve symptoms can significantly improve quality of life. Anoro Ellipta and Trelegy Ellipta are two such drugs prescribed for these conditions. They each have different mechanisms in action but both help to alleviate the breathlessness associated with COPD.
Anoro Ellipta is a combination of two bronchodilators: a long-acting muscarinic antagonist (LAMA), Umeclidinium, and a long-acting beta2-adrenergic agonist (LABA), Vilanterol. This combo works by relaxing muscles around the airways in your lungs, making it easier to breathe.
On the other hand, Trelegy Ellipta consists of three active ingredients: Fluticasone Furoate, an inhaled corticosteroid; Umeclidinium Bromide, a LAMA; and Vilanterol Trifenatate, a LABA. The addition of an inhaled corticosteroid provides added anti-inflammatory benefits which may be helpful for some patients with severe COPD or frequent exacerbations.
Anoro Ellipta vs Trelegy Ellipta Side By Side
| Attribute | Anoro ellipta | Trelegy ellipta |
|---|---|---|
| Brand Name | Anoro Ellipta | Trelegy Ellipta |
| Contraindications | Should not be used with beta-blockers or as rescue therapy for sudden breathing problems. | Should not be used with beta-blockers or as rescue therapy for sudden breathing problems. |
| Cost | $400 for a one-month supply | $600 for a one-month supply |
| Generic Name | Umeclidinium/Vilanterol | Fluticasone/Umeclidinium/Vilanterol |
| Most Serious Side Effect | Sudden breathing difficulties, signs of allergic reaction, vision changes, heart issues, high blood sugar, low potassium level. | Signs of an allergic reaction, chest pain or pressure, rapid eye movement causing vision disturbances, high blood sugar levels, low potassium level signs. |
| Severe Drug Interactions | Beta-blockers | Beta-blockers |
| Typical Dose | One inhalation once daily (62.5 mcg of umeclidinium and 25 mcg of vilanterol) | One inhalation per day (100mcg of fluticasone furoate, 62.5mcg of umeclidinium, and 25mcg of vilanterol) |
What is Anoro Ellipta?
Anoro Ellipta and Trelegy Ellipta are two different inhalation powders that play a significant role in treating chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis. Anoro Ellipta, approved by the FDA in 2013, combines two long-acting bronchodilators, Umeclidinium and Vilanterol. These work together to relax the muscles of your airways to improve breathing. It is used once daily for continuous 24-hour COPD symptom control.
Trelegy Ellipta on the other hand, which was first approved by the FDA in 2017, is a combination of three drugs: Fluticasone furoate (an inhaled corticosteroid), Umeclidinium (an anticholinergic), and Vilanterol (a long-acting beta2-adrenergic agonist). This triple action medication not only helps to relax and open your airways but also reduces inflammation within them. While both medications can effectively manage COPD symptoms with minimal side effects compared to their counterparts due to their targeted mechanisms of actions, Trelegy offers an added anti-inflammatory component making it potentially more beneficial for patients with severe COPD or those who have frequent exacerbations despite treatment with dual therapy.
What conditions is Anoro Ellipta approved to treat?
Anoro Ellipta is approved for the long-term maintenance treatment of airflow obstructions in patients with:
- Chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
- It is also used to reduce exacerbations of COPD in patients with a history of exacerbations.
Please note that Anoro Ellipta is not indicated for the relief of acute bronchospasm or for the treatment of asthma.
How does Anoro Ellipta help with these illnesses?
Anoro Ellipta helps manage Chronic Obstructive Pulmonary Disease (COPD) by increasing the amount of air flow to the lungs. It achieves this by relaxing and opening up the airways, making it easier for patients to breathe. Anoro Ellipta contains a combination of two drugs: Umeclidinium, which is an anticholinergic that works by blocking certain reflexes in the lungs to improve airflow; and Vilanterol, which is a long-acting beta2-adrenergic agonist that works by stimulating certain receptors in the lung muscles, causing them to relax and thus widen bronchial tubes.
On the other hand, Trelegy Ellipta also increases airflow but does so with three active ingredients: Fluticasone furoate (an anti-inflammatory steroid), Umeclidinium bromide (as in Anoro), and Vilanterol trifenatate (also as in Anoro). This triple-action approach not only relaxes and opens up airways but also decreases inflammation within them. Therefore, depending on a patient's specific needs – whether they require more bronchodilation or both bronchodilation with added anti-inflammatory action - either Anoro or Trelegy could be better suited for managing their COPD symptoms.
What is Trelegy Ellipta?
Trelegy Ellipta is a brand name for a combination of fluticasone furoate, umeclidinium, and vilanterol indicated in the treatment of chronic obstructive pulmonary disease (COPD), including bronchitis and emphysema. It's a triple therapy that works by reducing inflammation, relaxing muscles around the airways in the lungs to prevent wheezing and shortness of breath. Trelegy Ellipta was first approved by the FDA in 2017. Since it contains an additional component compared to Anoro Ellipta (fluticasone furoate, which is a corticosteroid), its effects are more comprehensive as it combines bronchodilation with anti-inflammatory action. This can lead to better symptom control and reduced exacerbations for patients with severe COPD or those who do not respond adequately to dual therapies such as Anoro Ellipta.
What conditions is Trelegy Ellipta approved to treat?
Trelegy Ellipta has been approved for the management of:
- Chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema
- Asthma in patients aged 18 years and older, providing a combination treatment with an inhaled corticosteroid, long-acting muscarinic antagonist, and a long-acting beta2-adrenergic agonist.
It is also indicated to reduce COPD exacerbations among patients who have had a history of exacerbations.
How does Trelegy Ellipta help with these illnesses?
Trelegy Ellipta, like Anoro Ellipta, acts on the bronchial smooth muscle in the lungs to help improve airflow and reduce symptoms associated with conditions such as chronic obstructive pulmonary disease (COPD). It does this by combining three different medications: an inhaled corticosteroid to reduce inflammation, a long-acting muscarinic antagonist to relax the airways, and a long-acting beta2-adrenergic agonist to further open up the airways. The unique aspect of Trelegy Ellipta is its triple-action mechanism that can provide more comprehensive symptom relief than dual-action drugs like Anoro Ellipta. This makes it particularly useful for patients with severe COPD or those who don't respond adequately to two-drug combinations.
How effective are both Anoro Ellipta and Trelegy Ellipta?
Both Anoro Ellipta and Trelegy Ellipta are inhalers used to manage symptoms of chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis. These medications were approved by the FDA in 2013 and 2017 respectively, thus indicating their reliability and efficacy for patients with COPD. They contain different combinations of active ingredients; Anoro contains a long-acting muscarinic antagonist (LAMA) vilanterol, and a long-acting beta2-adrenergic agonist (LABA) umeclidinium bromide while Trelegy also includes an inhaled corticosteroid called fluticasone furoate.
The effectiveness of both drugs was observed through various clinical trials over the years. For instance, a study conducted in 2020 found that patients using either medication had similar improvements in lung function tests. However, those given Trelegy did show slightly better results when it came to reducing exacerbations or flare-ups due to its added steroid component.
In terms of side effects profile, both have been well tolerated by most users but there might be small differences based on individual patient characteristics. The common side effects include upper respiratory tract infection, sore throat, cough among others which are typical for such class of medicines.
One comprehensive review from 2018 found that Anoro is effective at controlling the symptoms associated with COPD starting from first use itself without significant adverse reactions reported during trials.
On the other hand, another meta-analysis carried out in 2020 confirmed that adding fluticasone furoate makes Trelegy more effective than just LABAs/LAMAs alone at preventing severe flare-ups though potential risks associated with regular use of steroids should not be overlooked . Hence it's generally considered after standard treatments like LAMAs/LABAs have failed or as an addition to them especially for people who experience frequent exacerbations despite being on regular treatment regimen .
Further research indicates that each drug may offer unique benefits based on individual variations amongst patients such as severity & frequency of COPD exacerbations , coexisting asthma condition etc making personalized approach crucial while choosing between these two options .
Related trials for anoro ellipta and trelegy ellipta
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Anoro Ellipta typically prescribed?
The recommended dosage of Anoro Ellipta for adults with COPD, including chronic bronchitis and emphysema, is one inhalation once daily. Each dose contains 62.5 mcg of umeclidinium and 25 mcg of vilanterol. On the other hand, Trelegy Ellipta is also used for treating COPD but it combines three active ingredients: fluticasone furoate (100mcg), umeclidinium (62.5mcg) and vilanterol (25mcg). The standard dosage is one inhalation a day. It's important to remember that these medications are not designed to relieve sudden breathing problems and won't replace a rescue inhaler.
At what dose is Trelegy Ellipta typically prescribed?
Trelegy Ellipta treatment is typically initiated at a dosage of one inhalation per day. Each inhalation contains fluticasone furoate (an inhaled steroid), umeclidinium (a long-acting muscarinic antagonist, commonly known as an anticholinergic), and vilanterol (a long-acting beta2-adrenergic agonist). This combination provides around-the-clock relief for COPD symptoms, including chronic bronchitis and emphysema. The dose should not be increased or decreased without the supervision of a healthcare provider. It's important to note that Trelegy Ellipta does not replace the use of rescue inhalers and it should not be used more than once every 24 hours. If there's no significant improvement in symptoms after several weeks of treatment with Trelegy Ellipta, your doctor may need to reassess your medication regimen.
What are the most common side effects for Anoro Ellipta?
Common side effects of Anoro Ellipta can include:
- Upper respiratory tract infection
- Stuffiness and runny nose
- Sore throat and hoarseness
- Bronchitis (inflammation in the tubes leading to lungs)
- Urinary tract infection (UTI)
- Sinusitis (inflammation or swelling of the sinus lining)
- Pharyngitis (soreness in the back of the throat)
- Cough
- Oral/throat pain
- Constipation, diarrhea, nausea, vomiting
- Muscle spasms or stiffness
While Trelegy Ellipta may induce similar effects such as upper respiratory tract infections, bronchitis, sore throats and coughing. Other common potential side effects are:
- Back pain
- Gastroenteritis (upset stomach)
- Pneumonia
- Yeast infections
- Changes in taste sensation
It is important to remember that these medications have different active ingredients which target various aspects of chronic obstructive pulmonary disease. Consult your doctor for more personalized advice on choosing between these two treatments.
Are there any potential serious side effects for Anoro Ellipta?
Anoro Ellipta, like other long-acting bronchodilators, can cause potential side effects. These include:
- Sudden breathing difficulties immediately after inhaling your medicine
- Signs of allergic reaction such as skin rash; hives; itching; red, swollen, blistered or peeling skin with or without fever; wheezing and tightness in the chest or throat
- Swelling of the mouth, face, lips, tongue or throat
- Vision changes such as blurred vision and increased pressure in the eye (glaucoma)
- Heart issues represented by fast heartbeat and chest pain
- High blood sugar - frequent urination, thirstiness that continues
- Low potassium level symptoms including muscle cramps or weakness and irregular heartbeats
In rare cases:
- White patches on tongue/in mouth.
- Chest pain while coughing up blood.
If you experience any of these signs stop using Anoro Ellipta and seek immediate medical attention. It is important to note that Trelegy Ellipta may share similar side effects due to its bronchodilator component. It also contains an inhaled corticosteroid which can potentially lead to oral thrush (yeast infection) manifested as white patches in your mouth/throat.
What are the most common side effects for Trelegy Ellipta?
With Trelegy Ellipta, patients may experience:
- Dry mouth or throat
- Upper respiratory tract infection symptoms such as runny nose or sore throat
- Cough or hoarseness
- Difficulty breathing or shortness of breath
- Chest pain or tightness
- Fast or irregular heartbeat (palpitations)
- Nervousness
- Tremors
- Constipation
- Blurred vision
-Rashes on the skin. Remember that these side effects can also be associated with Anoro Ellipta, but the possibility to experience them might increase when using Trelegy Ellipta due to its additional active ingredient. It's always important to discuss any concerns about potential side effects with your healthcare professional.
Are there any potential serious side effects for Trelegy Ellipta?
Trelegy Ellipta, like Anoro Ellipta, is generally well-tolerated by most patients. However, it's important to be aware of potential severe side effects that may require immediate medical attention:
- Signs of an allergic reaction: hives; difficulty breathing; swelling in your face or throat
- Upper respiratory tract infection symptoms: fever, cough with mucus formation and difficult or painful urination
- Chest pain or pressure often accompanied by pain spreading to the jaw or shoulder
- Rapid eye movement causing vision disturbances
- High blood sugar levels which can cause increased thirst, frequent urination and unexplained weight loss
- Low potassium level signs such as leg cramps, constipation and irregular heartbeats
If you experience any of these symptoms while using Trelegy Ellipta do not ignore them. Immediately consult with your healthcare provider for further guidance.
Contraindications for Anoro Ellipta and Trelegy Ellipta?
Both Anoro Ellipta and Trelegy Ellipta, along with most other COPD medications, may worsen symptoms in some people. If you notice your breathing problems worsening or an increase in wheezing or shortness of breath, please seek immediate medical attention.
Neither Anoro Ellipta nor Trelegy Ellipta should be used if you are taking, or have been recently using medicines called beta-blockers (used to treat high blood pressure or heart conditions). Always tell your physician which medications you are taking; Beta-blockers will require a period of about 2 weeks to clear from the system to prevent dangerous interactions with Anoro and Trelegy Ellipta.
It’s also worth mentioning that both these drugs should not be used as rescue therapy for sudden breathing problems. A different medication should be used instead. It is important to always keep a quick-relief inhaler handy while using these two drugs.
How much do Anoro Ellipta and Trelegy Ellipta cost?
For the brand name versions of these drugs:
- The price for a one-month supply (30 doses) of Anoro Ellipta (umeclidinium/vilanterol 62.5mcg/25mcg) averages around $400, which works out to approximately $13/day.
- The price for a one-month supply (30 doses) of Trelegy Ellipta (fluticasone/umeclidinium/vilanterol 100mcg/62.5mcg/25mcg) is about $600, working out to roughly $20/day.
Thus, if you are considering between these two medications, Anoro Ellipta could be less expensive on a per-day treatment basis. However, please note that cost should not be the primary consideration in determining which of these drugs is right for you.
As it stands currently, there are no generic versions available for either Anoro or Trelegy Ellipta due to patent protection and exclusivity rights held by the manufacturers – so costs remain high compared to other classes of respiratory medications.
Popularity of Anoro Ellipta and Trelegy Ellipta
Anoro Ellipta and Trelegy Ellipta are both medications commonly used to treat Chronic Obstructive Pulmonary Disease (COPD).
In 2020, Anoro Ellipta was estimated to have been prescribed to about 1.3 million people in the US, accounting for approximately 10% of all prescriptions for COPD medication. The prevalence of Anoro use has steadily increased since its introduction in 2014.
On the other hand, Trelegy Ellipta, which is a newer option that contains an additional active ingredient compared to Anoro, was prescribed to around half a million individuals in the USA during the same year. Despite being on the market for less time than Anoro (it was approved by FDA only in 2017), Trelegy’s prescription rates are growing rapidly due to its triple-action mechanism that may offer superior benefits over dual-action drugs like Anoro for some patients with COPD.
Conclusion
Both Anoro Ellipta and Trelegy Ellipta are well-established medications for managing the symptoms of chronic obstructive pulmonary disease (COPD), with numerous clinical studies indicating they are more effective than placebo in improving lung function. Both drugs work by combining bronchodilators, which relax the muscles around the airways, allowing them to open up and make it easier to breathe.
The key difference between these two is that while Anoro contains two active components - a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA), Trelegy also includes an inhaled corticosteroid (ICS). This makes Trelegy potentially more beneficial for patients who have an elevated risk of exacerbations or those whose symptoms aren't adequately controlled with LAMA/LABA combination alone. However, this decision should be carefully reviewed by a healthcare provider as ICS use has been associated with an increased risk of pneumonia.
Both inhalers may take some time to show effects as bronchodilators don't provide immediate relief but rather control daily COPD symptoms over time.
Side effects are generally similar between both options, though due to its additional component, users of Trelegy may experience side effects related to corticosteroids such as oral thrush or hoarseness. For both treatments, any changes in breathing patterns or worsening symptoms should prompt immediate consultation with a healthcare professional.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Kelly, E. (2014, June 7). Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology. Informa UK Limited.http://doi.org/10.1586/17512433.2014.926812
- Scott, L. J., & Hair, P. (2014, February 15). Umeclidinium/Vilanterol: First Global Approval. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-014-0186-8
- Blair, H. A., & Deeks, E. D. (2014, November 15). Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-014-0326-1
- McKeage, K. (2014, July 30). Fluticasone Furoate/Vilanterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-014-0269-6
- Cazzola, M., Segreti, A., & Matera, M. G. (2013, October). New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Design, Development and Therapy. Informa UK Limited.http://doi.org/10.2147/dddt.s39449
- Ramadan, W. H., Al Masri, S., & Rizk, J. (2019, September 2). Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. The Clinical Respiratory Journal. Wiley.http://doi.org/10.1111/crj.13073
- Gras, J. (2014). Umeclidinium/vilanterol fixed-dose combination for COPD. Drugs of Today. Portico.http://doi.org/10.1358/dot.2014.50.3.2122119